AbbVie, AstraZeneca, and GSK are among the 10 companies now under scrutiny by the Federal Trade Commission, which is cracking down on businesses it says improperly or inaccurately placed items on a ...
After a clutch of lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book—the registry for patents of approved drugs—the Federal Trade Commission (FTC) is getting in on ...
As part of efforts to increase transparency and generic drug competition, the US Food and Drug Administration (FDA) is publishing patent submission dates to help generic drug manufacturers determine ...
For more than two years, the U.S. Federal Trade Commission (FTC) has been taking certain drugmakers to task over their alleged listing of "improper" patents in an FDA registry, a practice the agency ...
The Federal Trade Commission announced on Wednesday that Teva Pharmaceutical (TEVA), under pressure from the agency, has requested the removal of more than 200 patents improperly listed in the FDA’s ...
The US Food and Drug Administration has published a final draft guidance that addresses what’s expected when sponsors get complete response letters (CRL) to their abbreviated new drug applications ...
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results